FDA approves Oxbryta (Voxelotor), the first medicine specifically targeting the root cause of sickle cell disease

This article was originally published here

Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to

The post FDA approves Oxbryta (Voxelotor), the first medicine specifically targeting the root cause of sickle cell disease appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply